Aca­dia un­veils the pos­i­tive PhI­II it's tak­ing to FDA for ex­pand­ing Nu­plazid's use in psy­chosis

Aca­dia Phar­ma­ceu­ti­cals has bro­ken out the num­bers prop­ping up Nu­plazid’s sur­prise ear­ly win in a Phase III de­men­tia study and, ac­cord­ing to one an­a­lyst, it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.